Direct evidence in men for a role of endogenous oestrogens on gonadotrophin release

Acta Endocrinol (Copenh). 1981 Jun;97(2):145-9. doi: 10.1530/acta.0.0970145.

Abstract

In six healthy subjects serum oestradiol was selectively decreased by administering an aromatase activity inhibitor, hydrotestolactone (HT). After HT administration serum oestradiol (Oe2) decreased from 18.7 +/- 2.3 (SEM) to 6.7 +/- 0.6 pg/ml whereas testosterone (T) and dihydrotestosterone (DHT) blood levels were not modified. These oestradiol changes were associated with a significant increase in serum LH and FSH concentrations (P less than 0.001). The administration of tamoxifen, an oestrogen antagonist, to 5 subjects caused a sharp increase in LH and FSH levels (P less than 0.001). Oe2 was unchanged after the treatment with tamoxifen, whereas T levels were significantly higher. The sum of these data suggests that oestradiol under physiological conditions plays a specific role in the feedback mechanism of gonadotrophin release.

MeSH terms

  • Adolescent
  • Adult
  • Dihydrotestosterone / blood
  • Estradiol / blood*
  • Follicle Stimulating Hormone / blood*
  • Humans
  • Luteinizing Hormone / blood*
  • Male
  • Middle Aged
  • Pituitary Hormone-Releasing Hormones / pharmacology
  • Tamoxifen / pharmacology
  • Testolactone / analogs & derivatives*
  • Testolactone / pharmacology
  • Testosterone / blood

Substances

  • Pituitary Hormone-Releasing Hormones
  • Dihydrotestosterone
  • Tamoxifen
  • testololactone
  • Testosterone
  • Estradiol
  • Testolactone
  • Luteinizing Hormone
  • Follicle Stimulating Hormone